Osteoarthritis in year 2021: biochemical markers.

Biomarkers; Diagnosis; Osteoarthritis; Prognosis; Protein; Review; Biomarkers/blood; Humans; Osteoarthritis/blood; Osteoarthritis/diagnosis; Rheumatology; Biomedical Engineering; Orthopedics and Sports Medicine

Abstract :

[en] OBJECTIVE: To summarize recent scientific advances in protein-derived soluble biomarkers of osteoarthritis. DESIGN: A systematic search on the PubMed electronic database of clinical studies on protein-derived soluble biochemical markers of osteoarthritis in humans that were published between January 1st 2020 and March 31th 2021. The studies were selected on the basis of objective criteria and summarized in a table. Then they were described in a narrative review. RESULTS: Out of 1971 publications, 48 fulfilled all selection criteria and 16 were selected by the author for the narrative review. The papers were classified according their clinical significance as defined in the BIPEDS classification. Two papers investigated the "burden of disease", two were dedicated to "investigative biomarkers", four papers question the "prognosis", three the "efficacy of treatment" and five the "diagnosis and phenotyping" value of protein-derived biomarkers. CONCLUSIONS: Currently, biomarkers research is focused on their use as tools to identify molecular endotypes and clinical phenotypes and to facilitate patient screening and monitoring in clinical trials. This approach should allow a more targeted management of patients suffering from osteoarthritis.

Disciplines :

Rheumatology

Author, co-author :

Henrotin, Yves ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)

Language :

English

Title :

Osteoarthritis in year 2021: biochemical markers.

Alternative titles :

[fr] Arthrose en 2021: les marqueurs biologiques

Publication date :

2022

Journal title :

Osteoarthritis and Cartilage

ISSN :

1063-4584

eISSN :

1522-9653

Publisher :

W.B. Saunders Ltd, England

Volume :

Issue :

Pages :

237-248

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S1063458421009602?httpAccept=text/xml

Funding text :

YH is the founder and the president of Artialis SA. He also received consulting fees from Nestlé, Tilman SA, Naturex, Laboratoire Expanscience, Immunobio and Genequine. The authors also received funding from the Belgian Walloon Region under grant agreement N° 1320131 , 7781 and 6905 .

Available on ORBi :

since 05 June 2022

Statistics

Number of views

101 (5 by ULiège)

Number of downloads

165 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kraus, V.B., Karsdal, M.A., Osteoarthritis: current molecular biomarkers and the way forward. Calcif Tissue Int, 2020, 10.1007/s00223-020-00701-7 Epub ahead of print. PMID: 32367210.
Karsdal, M.A., Michaelis, M., Ladel, C., Siebuhr, A.S., Bihlet, A.R., Andersen, J.R., et al. Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthritis Cartilage 24:12 (2016), 2013–2021.
Henrotin, Y., Sanchez, C., Cornet, A., Van de Put, J., Douette, P., Gharbi, M., Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine. Biomarkers 20:8 (2015), 540–546.
Bay-Jensen, A.C., Henrotin, Y., Karsdal, M., Mobasheri, A., The need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA). EBioMedicine 7 (2016), 4–6.
Dell'Isola, A., Allan, R., Smith, S.L., Marreiros, S.S., Steultjens, M., Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord 17:1 (2016), 425–433.
Mobasheri, A., van Spil, W.E., Budd, E., Uzieliene, I., Bernotiene, E., Bay-Jensen, A.C., et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol 31:1 (2019), 80–89.
Mobasheri, A., Saarakkala, S., Finnilä, M., Karsdal, M.A., Bay-Jensen, A.C., van Spil, W.E., Recent advances in understanding the phenotypes of osteoarthritis. F1000Res, 12, 2019, 8 F1000 Faculty Rev-2091 https://doi.org/10.12688/f1000research.20575.1 PMID: 31885861; PMCID: PMC6913225.
Bauer, D.C., Hunter, D.J., Abramson, S.B., Attur, M., Corr, M., Felson, D., et al., Osteoarthritis Biomarkers Network. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:8 (2006), 723–727.
Liem, Y., Judge, A., Kirwan, J., Ourradi, K., Li, Y., Sharif, M., Multivariable logistic and linear regression models for identification of clinically useful biomarkers for osteoarthritis. Sci Rep 10:1 (2020), 11328–11335.
Rajandran, S.N., Ma, C.A., Tan, J.R., Liu, J., Wong, S.B.S., Leung, Y.Y., Exploring the association of innate immunity biomarkers with MRI features in both early and late stages osteoarthritis. Front Med (Lausanne) 7 (2020), 554–669.
Nair, A., Kanda, V., Bush-Joseph, C., Verma, N., Chubinskaya, S., Mikecz, K., et al. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14. Arthritis Rheum 64:7 (2012), 2268–2277.
Huang, Z., Kraus, V.B., Does lipopolysaccharide-mediated inflammation have a role in OA?. Nat Rev Rheumatol 12:2 (2016), 123–129.
Timur, U.T., Jahr, H., Anderson, J., Green, D.C., Emans, P.J., Smagul, A., et al. Identification of tissue-dependent proteins in knee OA synovial fluid. Osteoarthritis Cartilage 29:1 (2021), 124–133.
Gabay, O., Sanchez, C., Dvir-Ginzberg, M., Gagarina, V., Zaal, K.J., Song, Y., et al. Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model. Arthritis Rheum 65:1 (2013), 159–166.
Dvir-Ginzberg, M., Gagarina, V., Lee, E.J., Booth, R., Gabay, O., Hall, D.J., Tumor necrosis factor α-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. Arthritis Rheum 63:8 (2011), 2363–2373.
Batshon, G., Elayyan, J., Qiq, O., Reich, E., Ben-Aderet, L., Kandel, L., et al. Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrosenescence. Ann Rheum Dis 79:10 (2020), 1370–1380.
Swain, S., Sarmanova, A., Coupland, C., Doherty, M., Zhang, W., Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies. Arthritis Care Res (Hoboken) 72:7 (2020), 991–1000.
Courties, A., Sellam, J., Berenbaum, F., Metabolic syndrome-associated osteoarthritis. Curr Opin Rheumatol 29:2 (2017), 214–222.
Hall, A.J., Stubbs, B., Mamas, M.A., Myint, P.K., Smith, T.O., Association between osteoarthritis and cardiovascular disease: systematic review and meta-analysis. Eur J Prev Cardiol 23:9 (2016), 938–946.
Arnold, N., Rehm, M., Büchele, G., Peter, R.S., Brenner, R.E., Günther, K.P., et al. Growth differentiation factor-15 as a potent predictor of long-term mortality among subjects with osteoarthritis. J Clin Med 9:10 (2020), 3107–3116.
Rehm, M., Büchele, G., Peter, R.S., Brenner, R.E., Günther, K.P., Brenner, H., et al. Relationship between cardiac biomarker concentrations and long-term mortality in subjects with osteoarthritis. PLoS One, 15(12), 2020, e0242814.
Rehling, T., Bjørkman, A.D., Andersen, M.B., Ekholm, O., Molsted, S., Diabetes is associated with musculoskeletal pain, osteoarthritis, osteoporosis, and rheumatoid arthritis. J Diabetes Res, 2019, 2019 Dec 6, 6324348.
Dell'Isola, A., Vinblad, J., Lohmander, S., Svensson, A.M.R.N., PhD, Turkiewicz, A., et al. Understanding the role of diabetes in the osteoarthritis disease and treatment process: a study protocol for the Swedish Osteoarthritis and Diabetes (SOAD) cohort. BMJ Open, 9(12), 2019, e032923.
Chanchek, N., Gersing, A.S., Schwaiger, B.J., Nevitt, M.C., Neumann, J., Joseph, G.B., et al. Association of diabetes mellitus and biochemical knee cartilage composition assessed by T2 relaxation time measurements: data from the osteoarthritis initiative. J Magn Reson Imaging 47:2 (2018), 380–390.
Rogers-Soeder, T.S., Lane, N.E., Walimbe, M., Schwartz, A.V., Tolstykh, I., Felson, D.T., et al., Multicenter Osteoarthritis (MOST) Study Group. Association of diabetes mellitus and biomarkers of abnormal glucose metabolism with incident radiographic knee osteoarthritis. Arthritis Care Res (Hoboken) 72:1 (2020), 98–106.
Segal, N.A., Torner, J.C., Felson, D.T., Niu, J., Sharma, L., Lewis, C.E., et al. Knee extensor strength does not protect against incident knee symptoms at 30 months in the multicenter knee osteoarthritis (MOST) cohort. PM R 1:5 (2009), 459–465.
Segal, N.A., Anderson, D.D., Iyer, K.S., Baker, J., Torner, J.C., Lynch, J.A., et al. Baseline articular contact stress levels predict incident symptomatic knee osteoarthritis development in the MOST cohort. J Orthop Res 27:12 (2009), 1562–1568.
Karsdal, M.A., Byrjalsen, I., Alexandersen, P., Bihlet, A., Andersen, J.R., Riis, B.J., et al., CSMC021C2301/2 Investigators. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage 23:4 (2015), 532–543.
Bihlet, A.R., Bjerre-Bastos, J.J., Andersen, J.R., Byrjalsen, I., Karsdal, M.A., Bay-Jensen, A.C., Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: data from two phase III clinical trials. Semin Arthritis Rheum 50:6 (2020), 1374–1381.
Lindström, E., Rizoska, B., Tunblad, K., Edenius, C., Bendele, A.M., Maul, D., et al. The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. J Transl Med, 16(1), 2018, 56.
Lindström, E., Rizoska, B., Henderson, I., Terelius, Y., Jerling, M., Edenius, C., et al. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. J Transl Med, 16(1), 2018 May 9, 125.
Conaghan, P.G., Bowes, M.A., Kingsbury, S.R., Brett, A., Guillard, G., Rizoska, B., et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized controlled trial. Ann Intern Med 172:2 (2020), 86–95.
Intema, F., Van Roermund, P.M., Marijnissen, A.C., Cotofana, S., Eckstein, F., Castelein, R.M., et al. Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study. Ann Rheum Dis 70:8 (2011), 1441–1446.
Wiegant, K., van Roermund, P.M., Intema, F., Cotofana, S., Eckstein, F., Mastbergen, S.C., et al. Sustained clinical and structural benefit after joint distraction in the treatment of severe knee osteoarthritis. Osteoarthritis Cartilage 21:11 (2013), 1660–1667.
Watt, F.E., Hamid, B., Garriga, C., Judge, A., Hrusecka, R., Custers, R.J.H., et al. The molecular profile of synovial fluid changes upon joint distraction and is associated with clinical response in knee osteoarthritis. Osteoarthritis Cartilage 28:3 (2020), 324–333.
Nambi, G., Abdelbasset, W.K., Elsayed, S.H., Khalil, M.A., Alrawaili, S.M., Alsubaie, S.F., Comparative effects of virtual reality training and sensory motor training on bone morphogenic proteins and inflammatory biomarkers in post-traumatic osteoarthritis. Sci Rep, 10(1), 2020 Sep 28, 15864.
Bianchi, J., de Oliveira Ruellas, A.C., Gonçalves, J.R., Paniagua, B., Prieto, J.C., Styner, M., et al. Osteoarthritis of the Temporomandibular Joint can be diagnosed earlier using biomarkers and machine learning. Sci Rep, 10(1), 2020, 8012.
Takegami, N., Akeda, K., Yamada, J., Sano, T., Murata, K., Huang, J., et al. RANK/RANKL/OPG system in the intervertebral disc. Arthritis Res Ther, 19(1), 2017, 121.
Liang, Q.Q., Li, X.F., Zhou, Q., Xing, L., Cheng, S.D., Ding, D.F., et al. The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. Bone 48:6 (2011), 1362–1369.
Goode, A.P., Schwartz, T.A., Kraus, V.B., Huebner, J.L., George, S.Z., Cleveland, R.J., et al. Inflammatory, structural, and pain biochemical biomarkers may reflect radiographic disc space narrowing: the Johnston County Osteoarthritis Project. J Orthop Res 38:5 (2020), 1027–1037.
Marnell, L., Mold, C., Du Clos, T.W., C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117:2 (2005), 104–111.
Skjøt-Arkil, H., Schett, G., Zhang, C., Larsen, D.V., Wang, Y., Zheng, Q., et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol 30:3 (2012), 371–379.
Bay-Jensen, A.C., Bihlet, A., Byrjalsen, I., Andersen, J.R., Riis, B.J., Christiansen, C., et al. Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis. Sci Rep, 11(1), 2021, 6583.
Manicourt, D.H., Poilvache, P., Van Egeren, A., Devogelaer, J.P., Lenz, M.E., Thonar, E.J., Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 43:2 (2000), 281–288.
Garcia, J.P., Utomo, L., Rudnik-Jansen, I., Du, J., Zuithoff, N.P.A., Krouwels, A., et al. Association between oncostatin M expression and inflammatory phenotype in experimental arthritis models and osteoarthritis patients. Cells, 10(3), 2021, 508.
Luo, Y., Samuels, J., Krasnokutsky, S., Byrjalsen, I., Kraus, V.B., He, Y., et al. A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis. J Orthop Traumatol, 22(1), 2021, 10.
van Spil, W.E., Szilagyi, I.A., Osteoarthritis year in review 2019: biomarkers (biochemical markers). Osteoarthritis Cartilage 28:3 (2020), 296–315.
van Helvoort, E.M., van Spil, W.E., Jansen, M.P., Welsing, P.M.J., Kloppenburg, M., Loef, M., et al. Cohort profile: the Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers. BMJ Open, 10(7), 2020, e035101.
Taylor, J., Dekker, S., Jurg, D., Skandsen, J., Grossman, M., Marijnissen, A.K., et al. APPROACH research consortium and APPROACH Principal Investigators. Making the patient voice heard in a research consortium: experiences from an EU project (IMI-APPROACH). Res Involv Engagem, 7(1), 2021 May 10, 24.